FAPi-46
Carcinoma, Intraductal, Noninfiltrating
Universität MünsterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Carcinoma, Intraductal, Noninfiltrating cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ROPIVACAINE Zealand University Hospital | Phase 4 | BB |
SUFENTANYL Zealand University Hospital | Phase 4 | BB |
TAMOXIFEN Northwestern University | Phase 3 | BB |
Metformin M.D. Anderson Cancer Center | Phase 3 | BB |
TAMOXIFEN National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
FAPi-46 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →